Ceva Animal Health (Ceva), the world’s fifth-largest animal health company, said the Singapore-based global investment firm Temasek has renewed its investment in the company.

Ceva announced in a statement on Monday the restructuring of its capital.

According to the statement, all investors including pure investors led by Temasek, have renewed their investment, demonstrating their confidence in the company’s ability to continue its sustained growth.

It noted the long-standing minority investors have renewed their commitment, demonstrating their confidence in the company’s future.

Leading this group of partners is Temasek, joined by French investors EMZ and Sagard, Asia-based HOPU Investments, and U.S.-based Continental Grain Company.

This sixth funding round also welcomes the addition of the French investment fund ARCHIMED, led by veterinarian Dr. Denis Ribon.

Specializing in the healthcare sector, ARCHIMED focuses on supporting companies in expanding internationally and accelerating their research programs.

Ceva’s management, led by Dr. Marc Prikazsky, has reinforced its participation and still retains the majority of voting rights, reaffirming the company’s commitment to remaining
independent.

It is supported by a core group of long-term investors, ensuring a stable and committed shareholding structure for the group’s development.

With 7,000 employees, Ceva is a global leader in animal health, particularly in vaccination.

Operating directly in 47 countries, the company delivers its products, services and equipment’s worldwide to veterinarians, livestock professionals, and pet owners.

To support innovation in animal health, the Bettencourt-Meyers and Mérieux families have increased their stake through the investment holding Téthys Invest and Mérieux Institute that joined forces with investment fund Mérieux Equity Partners.

Canadian pension investor PSP Investments, a long-term investor in Ceva, has also significantly increased its ownership in the group.

Other companies participating include Sofiprotéol, the investment branch of the French group Avril, the Japanese company Mitsui & Co., as well as some local investment funds and the Klocke family.

Since its founding in 1999, Ceva has grown its revenue fourteenfold, reaching €1.77 billion ($1.92 billion) last year.

Driven by innovation and deeply committed to preventive medicine, the firm was the first veterinary company to develop and commercialize a cutting-edge nucleotide vaccine and invest in gene therapy for companion animals.

Aware of its responsibility in addressing major global challenges, the firm said it is strongly committed to reducing its environmental impact and promoting the preservation of animal biodiversity.

“I am delighted to see that in this new round of financing, the management’s participation, supported by the ‘Friends of Ceva’, is being strengthened alongside our historic financial investors and new entrants,” said Dr. Marc Prikazsky, Chairman and Chief Executive Officer of Ceva Animal Health.

“Ceva plays a major role in animal health, particularly in the fight against emerging diseases, sometimes zoonotic, and in the treatment of chronic diseases affecting our loyal four-legged companions,

“At Ceva, we are convinced that we must continue to create bridges between different health sectors to protect the health of ecosystems and humans as well as global food security,” he added.

#CevaAnimalHealth #VeterinaryInnovation #AnimalVaccines #OneHealth #SustainableFarming